Ainos Inc AIMD

Healthcare Biotechnology

Ainos, Inc. is engaged in developing medical technologies for point-of-care (POCT) testing and medical treatment for a range of disease indications. The Company is engaged in the research and clinical development activities for its programs, securing related intellectual property, and commercializing therapeutics using low-dose non-injectable interferon (IFN). Its Medtech solutions includes COVID-19 Antigen Rapid Test Kit, Volatile Organic Compounds (VOC) POCT-Ainos Flora, VOC POCT-Ainos Pen, VOC POCT-CHS430, Very Low-Dose Oral Interferon Alpha (VELDONA) and Synthetic RNA (SRNA). Its Ainos Flora device is intended to perform a non-invasive test for female vaginal health and certain common sexually transmitted diseases (STDs). Ainos Pen device is a cloud-connected, multi-purpose, portable breath analyzer that is intended to monitor health conditions. The CHS430 device is intended to provide non-invasive testing for ventilator-associated pneumonia.

NDAQ:AIMD - Post by User

Ainos Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Sep 25, 2024 11:33am

30 Views

Post# 36240296

Ainos, Inc. Receives IRB Approval From National Taiwan Unive

Breaking News: $AIMD Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONANext step will be receiving approval from Taiwan Food and Drug Administration (TFDA) SAN DIEGO, CA / ACCESSWIRE / September 25, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("PO...AIMD - Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA

<< Previous

Bullboard Posts

Next >>

Covalon Technologies posts third profitable quarter in a row